Olutasidenib Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as RIGEL PHARMS. It is marketed under 1 brand name, including REZLIDHIA. Available in 1 different strength, such as 150MG, and administered through 1 route including CAPSULE;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"109876","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5069b16c3f8a45c6b004","publication_number":"US10414752B2","cleaned_patent_number":"10414752","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2019-09-17","legal_status":"Granted"} US10414752B2 Formulation 17 Sep, 2019 Granted 18 Sep, 2035
{"application_id":"109877","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5069b16c3f8a45c6b004","publication_number":"US10550098B2","cleaned_patent_number":"10550098","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2020-02-04","legal_status":"Granted"} US10550098B2 Formulation 04 Feb, 2020 Granted 18 Sep, 2035
{"application_id":"109879","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5069b16c3f8a45c6b004","publication_number":"US11498913B2","cleaned_patent_number":"11498913","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2022-11-15","legal_status":"Granted"} US11498913B2 Formulation 15 Nov, 2022 Granted 18 Sep, 2035
{"application_id":"164401","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5069b16c3f8a45c6b004","publication_number":"US12275715B2","cleaned_patent_number":"12275715","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2025-04-15","legal_status":"Granted"} US12275715B2 Molecular Formulation 15 Apr, 2025 Granted 18 Sep, 2035
{"application_id":"109807","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5069b16c3f8a45c6b004","publication_number":"US9834539B2","cleaned_patent_number":"9834539","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-09-18","publication_date":"2017-12-05","legal_status":"Granted"} US9834539B2 Molecular Formulation 05 Dec, 2017 Granted 18 Sep, 2035
{"application_id":"109776","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5ad0572169cd4c9db044","publication_number":"US11013734B2","cleaned_patent_number":"11013734","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-05-16","publication_date":"2021-05-25","legal_status":"Patented case"} US11013734B2 25 May, 2021 Patented case 16 May, 2039
{"application_id":"129405","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5ad0572169cd4c9db044","publication_number":"US11376246B2","cleaned_patent_number":"11376246","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-05-16","publication_date":"2022-07-05","legal_status":"Patented case"} US11376246B2 05 Jul, 2022 Patented case 16 May, 2039
{"application_id":"129406","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5ad0572169cd4c9db044","publication_number":"US11497743B2","cleaned_patent_number":"11497743","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-05-16","publication_date":"2022-11-15","legal_status":"Granted"} US11497743B2 15 Nov, 2022 Granted 16 May, 2039
{"application_id":"130691","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5ad0572169cd4c9db044","publication_number":"US12053463B2","cleaned_patent_number":"12053463","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-05-16","publication_date":"2024-08-06","legal_status":"Granted"} US12053463B2 Molecular Formulation 06 Aug, 2024 Granted 16 May, 2039
{"application_id":"109774","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5ad0572169cd4c9db044","publication_number":"US10959994B2","cleaned_patent_number":"10959994","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-05-16","publication_date":"2021-03-30","legal_status":"Granted"} US10959994B2 Formulation 30 Mar, 2021 Granted 16 May, 2039
{"application_id":"109775","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5ad0572169cd4c9db044","publication_number":"US11013733B2","cleaned_patent_number":"11013733","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-05-16","publication_date":"2021-05-25","legal_status":"Granted"} US11013733B2 25 May, 2021 Granted 16 May, 2039
{"application_id":"129400","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5ad0572169cd4c9db044","publication_number":"US10532047B2","cleaned_patent_number":"10532047","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-05-16","publication_date":"2020-01-14","legal_status":"Patented case"} US10532047B2 Molecular 14 Jan, 2020 Patented case 16 May, 2039
{"application_id":"109782","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5ad0572169cd4c9db044","publication_number":"US11738018B2","cleaned_patent_number":"11738018","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-07-17","publication_date":"2023-08-29","legal_status":"Patented case"} US11738018B2 29 Aug, 2023 Patented case 17 Jul, 2039
{"application_id":"129408","ingredient":"OLUTASIDENIB","trade_name":"REZLIDHIA","family_id":"5ad0572169cd4c9db044","publication_number":"US11723905B2","cleaned_patent_number":"11723905","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-11-12","publication_date":"2023-08-15","legal_status":"Patented case"} US11723905B2 Formulation 15 Aug, 2023 Patented case 12 Nov, 2039

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Olutasidenib

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.